Carrico J, Mellott CE, Talbird SE, Bento-Abreu A, Merckx B, Vandenhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Eiden A, Nyaku MK, Bencina G. Public health impact and return on investment of Belgium's pediatric immunization program. Front Public Health. 2023 Jun 22;11:1032385. doi: 10.3389/fpubh.2023.1032385
Kelkar SS, Prabhu VS, Zhang J, Corman S, Macahilig C, Rusibamayil N, Odak S, Duska LR. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States. Gynecol Oncol Rep. 2022 Aug 1;42(2022):101026. doi: 10.1016/j.gore.2022.101026
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.